Learn More-External Link
Trending at Lumira Ventures
Morphotek CEO Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner
Learn More-External Link
MAKO Surgical Corp. CEO is named Ernst & Young Entrepreneur Of The Year
FORT LAUDERDALE, Fla. – MAKO Surgical Corp. announced today that its President & CEO Maurice R. Ferré, M.D., has received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. The Ernst & Young Entrepreneur …
Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
Learn More-External Link
Healthcare Acquisition Corp. and Pharmathene receive stockholder approval for their merger
DES MOINES, IA and ANNAPOLIS, MD, August 3, 2007 – Healthcare Acquisition Corp. (AMEX: HAQ), a publicly-traded special purpose acquisition company, and PharmAthene, Inc., a biodefense company developing and commercializing medical countermeasures againstbiological and chemical threats, today announced that the …
Alexza Pharmaceuticals Expands Staccato(R) Migraine Product Portfolio
Learn More-External Link
Archemix and Merck KGaA Sign Strategic Alliance
Cambridge, MA – June 11, 2007 – Archemix Corp. and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that they have formed a multi-year strategic alliance to discover, develop and commercialize first-in-class aptamer therapeutics with a primary focus …
Archemix and Takeda to Enter into Collaboration for Discovery and Development …
Cambridge, MA and Osaka, Japan — June 11, 2007 — Archemix Corp. (“Archemix”) and Takeda Pharmaceutical Company Limited (“Takeda “) announced today that both parties have signed a multi-year, three target agreement that focuses on the discovery, development and commercialization of first-in-class aptamer-based therapeutics. Under …
Archemix Announces Completion of Phase 1 Trial of ARC1779
Learn More-External Link
MAKO Surgical Corp. Names Charles W. Federico to Board of Directors
FORT LAUDERDALE, Fla. (June 6, 2007) – MAKO Surgical Corp., a developer of minimally invasive, robotic-enabled techniques for knee surgery, announced today that Charles W. Federico has been named to the company’s Board of Directors, effective June 5. Federico has …
FierceBiotech Names Archemix Corp. as One of the “Fierce 15″ Biotech Companies of 2007
June 06, 2007 10:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Archemix Corp. today announced it has been named to the annual FierceBiotech “Fierce 15”list, designating it as one of the top biotech companies of 2007. The editors of FierceBiotech evaluated hundreds …
Clinical Data on Eisai’s Oncology Pipeline to be Presented at ASCO Annual Meeting
Learn More-External Link
Ception Therapeutics Raises Additional $14.7 Million Bringing Total Series C Fina…
Learn More-External Link
KAI Pharmaceuticals Initiates Phase 1 Trial of KAI-1455 for Ischemic Injury
Learn More-External Link
Pharmasset Completes Enrollment of Phase 1 Study of R7128 for HCV
Learn More-External Link